Navigation Links
Health Leaders Issue Recommendations to Improve Management of a Common, Costly and Misunderstood Cardiovascular Disease: Atrial Fibrillation
Date:9/16/2009

"AF Stat(TM) Call to Action for Atrial Fibrillation" Report Cites Limited Understanding, Disconnected Dialogue and Uncoordinated Care as Key Barriers to Improved Outcomes

WASHINGTON, Sept. 16 /PRNewswire-USNewswire/ -- A diverse collaboration of healthcare leaders today released the AF Stat(TM) Call to Action for Atrial Fibrillation to serve as a roadmap for reducing the burden of atrial fibrillation (AFib) in the United States. The document outlines critical issues surrounding the management of AFib, and recommends priority actions in the areas of policy, management, education and quality.

"For far too long, AFib has flown under the radar of many healthcare professionals, policymakers and the public," said Senator Bill Frist, M.D., former Senate Majority Leader and health policy advisor for AF Stat. "AFib disproportionately affects Medicare patients, yet the disease's impact on both individuals and our healthcare system has never been fully defined or prioritized."

Characterized by an irregular and frequently fast heartbeat, AFib is the most common form of heart arrhythmia. It affects approximately 2.5 million Americans, and its prevalence is expected to increase as the U.S. population ages. AFib is associated with a five-fold increase in risk for stroke(1); worsens underlying cardiovascular disease(2); and doubles the risk of all-cause mortality(3).

The disease is also expensive, costing the nation approximately $6.65 billion annually, much of which could be attributed to the increased hospital in-patient, emergency and medical services utilization rates for people with AFib(4). A report released today by Avalere Health, Medicare and Atrial Fibrillation: Consequences in Cost and Care references research estimating that costs associated with AFib may be as high as $15.7 billion(5) per year, further reinforcing the need to prioritize AFib.

The report describes the burden of AFib on Medicare, and offers strategies to enhance quality of care, improve patient outcomes and reduce healthcare costs associated with the disease. The report was prepared and funded as an outcome of AF Stat, a first-of-its-kind, national initiative that aims to elevate understanding, diagnosis and management of AFib among all those affected by this serious and increasingly prevalent cardiovascular disease.

AF Stat(TM) Call to Action for Atrial Fibrillation Key Insights

The AF Stat Call to Action provides recommendations for four priority actions to reduce the burden of atrial fibrillation:

  • Policy and Advocacy - Educate and inform key stakeholders about the health risks associated with AFib and the importance of comprehensive management.
  • Education - Make tools available for all AFib stakeholders to facilitate greater understanding about its risks and the need for comprehensive early management, and to heighten awareness of the disease.
  • Management - Achieve accurate diagnosis and comprehensive management across medical practices and between medical specialties.
  • Quality - Define best practices in AFib management, align clinical practice guidelines and implement performance measures to improve patient outcomes.

"Historically, there has been a disappointing lack of urgency to change the status quo surrounding AFib," said Eric Prystowsky, M.D., AF Stat Medical Chair and Director of the Clinical Electrophysiology Laboratory, St. Vincent Hospital in Indianapolis. "This Call to Action provides key public health directives that can motivate change and improve the understanding and management of AFib."

To further help determine what actions to tackle first, AF Stat invites anyone affected by, or interested in AFib to go to www.AFStat.com to rank recommended priority actions.

About the "AF Stat(TM): A Call to Action for Atrial Fibrillation" report

The recommendations presented in the AF Stat Call to Action were compiled through interviews and meetings with members of AF Stat - a collaboration of 24 organizations and individuals representing the advocacy, medical, government, professional, aging, caregiver, employer, payer and cardiovascular sectors. Together, AF Stat aims to elevate understanding, diagnosis and management of AFib among all parties affected by the disease. AF Stat is sponsored by sanofi-aventis U.S. LLC, which provided funding for this report.

About the Medicare and Atrial Fibrillation: Consequences in Cost and Care report

Medicare and Atrial Fibrillation: Consequences in Cost and Care was written by Avalere Health and funded by sanofi-aventis U.S. LLC, which is the sponsor for AF Stat. Avalere maintained editorial control and the conclusions expressed in the report are those of the author.

About AF Stat(TM)

AF Stat is a collaboration of healthcare leaders and organizations working to improve the health and well-being of people affected by atrial fibrillation. AF Stat is raising awareness of AFib as a complex, costly, progressive and often debilitating disease. It also is calling for and helping promote a change in attitudes and behaviors to enhance AFib understanding, diagnosis and management. AF Stat is sponsored by sanofi-aventis U.S. LLC. More information can be found at www.AFStat.com

AF Stat is an initiative sponsored by sanofi-aventis U.S. LLC, which also funded the Medicare and Atrial Fibrillation: Consequences in Cost and Care report.

(1) Wolf PA, Abbott RD, Kannel, WB. Atrial fibrillation as an independent risk factor for stroke:

the Framingham Study. Stroke. 1991;22;983-988.

(2) Fuster V, Ryden LE, Cannom DS, et al.

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257-e354.

(3) Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.

(4) Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds MR, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health.

2006;9:348-356.

(5) Lee W. Lamas G. Balu S., et al. "Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective." Journal of Medical Economics 11 (2008): 281-298. $15.7 billion is calculated as follows: from a 5% Medicare sample size the study identifies patients with AF and non-AF. The difference in cost for these two populations is $14,199 more for the AF population compared to non-AF. Since this is a sample size, the costs need to be extrapolated to the full population. Therefore, $14,199 multiplied by the sample size of 55,260, multiplied by 20 to reflect 100% of the Medicare population.

    Contact: Tom Murphy
    Chandler Chicco Agency
    202-368-8571
    tmurphy@ccapr.com


'/>"/>
SOURCE AF Stat Working Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: